Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Published:2017-09-29 Issue:4 Volume:179 Page:586-597
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Einsele Hermann¹^ORCID,Engelhardt Monika²^ORCID,Tapprich Christoph³,Müller Jürgen⁴,Liebisch Peter⁵,Langer Christian⁵,Kropff Martin⁶,Mügge Lars O.⁷,Jung Wolfram⁸,Wolf Hans-Heinrich⁹,Metzner Bernd¹⁰,Hart Christina¹¹,Gramatzki Martin¹²,Hertenstein Bernd¹³,Pfreundschuh Michael¹⁴^ORCID,Rösler Wolf¹⁵,Fischer Thomas¹⁶,Maschmeyer Georg¹⁷,Kanz Lothar¹⁸,Hess Georg¹⁹,Jäger Elke²⁰,Bentz Martin²¹,Dürk Heinz A.²²,Salwender Hans²³,Hebart Holger²⁴,Straka Christian²⁵,Knop Stefan¹

Affiliation:

1. University Hospital Würzburg; Würzburg Germany

2. University Hospital Freiburg; Freiburg Germany

3. Janssen-Cilag GmbH; Neuss Germany

4. Acromion GmbH; Frechen Germany

5. University Hospital Ulm; Ulm Germany

6. University Hospital Munster; Munster Germany

7. University Hospital Jena; Jena Germany

8. University Hospital Gottingen; Gottingen Germany

9. University Hospital Halle; Halle Germany

10. Klinikum Oldenburg; University Hospital; Oldenburg Germany

11. University Hospital Regensburg; Regensburg Germany

12. University Hospital Schleswig-Holstein; Kiel Germany

13. Hospital Bremen-Mitte; Bremen Germany

14. University Hospital of Saarlandia; Homburg Germany

15. University Hospital Erlangen; Erlangen Germany

16. University Hospital Magdeburg; Magdeburg Germany

17. Klinikum Ernst von Bergmann; Potsdam Germany

18. University Hospital Tübingen; Tübingen Germany

19. University Medical Centre of the Johannes Gutenberg University Mainz; Mainz Germany

20. Northwest Hospital; Frankfurt Germany

21. City Hospital Karlsruhe; Karlsruhe Germany

22. St. Mary Hospital Hamm; Hamm Germany

23. Asklepios Clinic Altona; Hamburg Germany

24. Stauferklinikum Schwäbisch Gmünd; Mutlangen Germany

25. Schön Klinik Starnberger See; Berg Germany

Funder

Millennium Pharmaceuticals, Inc.

Janssen Global Services, LLC

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14920/fullpdf

Reference56 articles.

1. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma;Ahn;Annals of Hematology,2012

2. Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology;Anderson;Journal of the National Comprehensive Cancer Network,2015

3. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature;Argyriou;Blood,2008

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;New England Journal of Medicine,1996

5. Stem cell transplantation in multiple myeloma;Attal;Hematology: The Education Program of the American Society of Hematology,2007

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients;Annals of Saudi Medicine;2024-03

2. Real life data comparing weekly VCD and twice weekly VCD protocols in newly diagnosed multiple myeloma patients;Turkish Journal of Internal Medicine;2024-01-29

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

4. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma;Transfusion and Apheresis Science;2023-06

5. An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence;Haematologica;2022-11-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3